IMpower150 Data for Immunotherapy Quadruplet in EGFR-Mutant Lung Cancer
Edward B. Garon, MD, discusses data from the IMpower150 trial where patients with <em>EGFR-</em>mutant lung cancer were randomized to 1 of 3 arms: a control of carboplatin, paclitaxel, and bevacizumab (Avastin), an arm replacing bevacizumab with atezolizumab (Tecentriq), and a third using all 4 agents.
Edward B. Garon, MD, director of thoracic oncology at the David Geffen School of Medicine at UCLA, discusses data from the IMpower150 trial where patients withEGFR-mutant lung cancer were randomized to 1 of 3 arms: a control of carboplatin, paclitaxel, and bevacizumab (Avastin), an arm replacing bevacizumab with atezolizumab (Tecentriq), and a third using all 4 agents.
Garon says the quadruplet regimen held the most benefit in respect to progression-free survival and also suggested an advantage in overall survival as well, despite a hazard ratio over 1. However, there was no clear benefit when atezolizumab was substituted for bevacizumab.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
